A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety concerns emerging.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/tyk2-inhibitor-promising-moderate-severe-psoriasis-phase-3-2026a10009tm?src=rss
Author :
Publish date : 2026-03-31 18:13:00
Copyright for syndicated content belongs to the linked Source.
